Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected, Treatment-Experienced HIV Patients

REFERENCES

• Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing pro-tease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29:41–48.
   PubMed Web of Science ®Google Scholar
• Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426–431.
   PubMed Web of Science ®Google Scholar
• Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23–31.
   PubMed Web of Science ®Google Scholar
• Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36–43.
   PubMedGoogle Scholar
• Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 200115: 1261–1268.
   Google Scholar
• Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S90–97.
   PubMed Web of Science ®Google Scholar
• Havlir DV, O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004;38:1599–1604.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603–2614.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685–694.
   PubMed Web of Science ®Google Scholar
• Mallolas J, Podzamczer D, Domingo P, et al. Efficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study. In: Pro-gram and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Pre-vention; July 22–25, 2007; Sydney, Australia. Abstract WEPEB117LB.
   Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavirversustwice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. Epub August 2, 2008. D01:10.1016/50140–6736 (08)61081–8.
   Google Scholar
• Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother. 2004;38:1664–1674.
   PubMed Web of Science ®Google Scholar
• Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxic-ity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003;32:259–267.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepa-totoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 200127: 316–318.
   Google Scholar
• Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coin-fection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis. 1995;172:1503–1508.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277–2284.
   PubMed Web of Science ®Google Scholar
• Lopinavir/ritonavir (LPV/r) Safety, tolerability and efficacy and liver safety in HC and/or Hep B-infected patients: review of Kaletra trials. In: Program and abstracts of the XV World AIDS Conference; 2004; Bangkok. Abstract B3285.
   Google Scholar
• Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combina-tion with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011–1019.
   PubMed Web of Science ®Google Scholar
• Youle M, Gerstoft J, Fox Z, et al. The final 48 week analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin2 trial. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment; 2003. Poster LB23.
   Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. Epub August 2, 2008. D01:10.1016/S0140–6736(08)61081–8.
   PubMed Web of Science ®Google Scholar
• Pineda JA, Palacios R, Rivero A, et al. Low incidence of severe liver toxicity in patients receiving antiretroviral com-binations including atazanavir. J Antimicrob Chemother. 2006;57:1016–1017.
   PubMed Web of Science ®Google Scholar